Close

Barclays 2012 Top Picks: Becoming Somewhat More Optimistic - Signs of Progress, Growth and Soft Landings Dec 13, 2011 11:39AM
Barclays Mintains an 'Overweight' on Bristol-Myers (BMY); Steady Pipeline Execution in Q3: November an Icremental Mnth for Eliquis Oct 28, 2011 03:04PM
Notable Analyst Rating Changes 10/28: (AMD) (LLY) (GS) Upgraded; (MDR) (BMY) (ED) Downgraded Oct 28, 2011 10:53AM
Barclays on U.S. Major Pharmaceuticals: Q3 Preview: BMY and PFE to Stand Apart From the Defensive Play Story Oct 13, 2011 02:32PM
Pre-Open Movers 9/19: (GR) (TYC) (LEN) Higher; (JKS) (AMAT) (RAH) Lower (more...) Sep 19, 2011 09:25AM


Sep 14, 2011 12:45PM UPDATE - Barclays Downgraded Pfizer (PFE) to Equalweight; Inferior Revenue Recovery Post 'Patent Cliff' Through 2020
Jul 22, 2011 02:49PM Barclays Maintains an 'Equalweight' on Eli Lilly (LLY); No Signs of Fatigue at the Edge of the Cliff; Pipeline Risk Unabated
Jul 13, 2011 01:11PM Barclays on U.S. Diagnostics: FDA Issues draft guidance on companion diagnostics; Positive read for QGEN
Jun 23, 2011 03:27PM Barclays Maintains an 'Overweight' on Bristol-Myers (BMY); ARISTOTLE Delivers One-Two Punch; Eliquis Poised to be the Market Leader
Jun 16, 2011 02:23PM Barclays Maintains an 'Overweight' on Bristol-Myers Squibb (BMY); Nulojix Marks Second Hit in a Row; ARISTOTLE Top Line Remains The Focus
Jun 10, 2011 03:21PM Barclays on U.S. Major Pharmaceuticals: Pipelines Revived? Making Strides in Oncology, Cardiology, and Virology
May 16, 2011 02:05PM Global Pharmaceuticals: Global Therapeutic Conference 2011: Focus on Real-World Medicine
Apr 18, 2011 01:19PM Barclays Maintains an 'Overweight' on Bristol-Myers (BMY); Management Dinner Feedback: Myriad Options, but How to Go Foward in HCV?
Apr 14, 2011 01:25PM Barclays on U.S. Major Pharmaceuticals: 1Q11 Preview: Restructuring or New Products - Which Is The Lifeline For Pharma?
Apr 6, 2011 12:58PM Barclays Maintains an 'Overweight' on Bristol-Myers Squibb (BMY); Leading in the Evolving HCV Landscape
Mar 28, 2011 01:27PM Barclays Maintains an 'Overweight' on Bristol-Myers Squibb (BMY); Ipilimumab: Two Birds with One Stone
Jan 24, 2011 02:50PM Barclays on U.S. Major Pharmaceuticals: U.S. Major Pharma 2011 Outlook: A View Beyond the Cliff
Nov 19, 2010 01:55PM Barclays Maintains an 'Overweight' on Bristol-Myers Squibb (BMY); APPRAISE-2 Discontinuation Has Limited Implications for ARISTOTLE
Oct 14, 2010 04:22PM U.S. Major Pharmaceuticals: Q3 Preview: A hit but not a home run
Oct 4, 2010 09:24AM Daily State of the Markets 10/04: Pressing Pause (Again)
Jul 15, 2010 02:02PM Barclays Maintains an 'Overweight' on Bristol-Myers (BMY); Expect Outperformance With Core Franchise Stability
Mar 5, 2010 10:27AM Notable Analyst Rating Changes 03/05: DISH, TIVO, CWTR, CIEN, BMY Upgraded; WEN, TSN, AUY, WBD Downgraded
Jan 4, 2010 10:38AM Notable Analyst Rating Changes: MS, BA, UNH, INTC, UPL, FTO, More Upgraded; BMY, CHK, BSX, MELI, More Downgraded
Dec 22, 2009 10:41AM Notable Analyst Rating Changes 12/22: ATHX, IAG, BUCY, AMTD Upgraded; XTO, IMAX, WRC Downgraded
Nov 17, 2009 02:50PM Barclays Maintains an 'Overweight' on Bristol-Myers (BMY); Raises PT
Jul 15, 2009 10:14AM Notable Analyst Rating Changes 7/15: GS, ALU, ICE, MCO, ADBE, MI Upgraded; PTR, PAR, UFS, PCL Downgraded
Apr 29, 2009 10:09AM David Moenning's Daily State of the Markets: 4/29
Apr 29, 2009 09:57AM Notable Analyst Rating Changes 4/29: ATVI, OZM, AMX, DNDN Upgraded; BMY, WFMI, M, SFD Downgraded
Apr 3, 2009 09:49AM Notable Analyst Rating Changes 4/3: RIMM, DVN, ICE, ELN Upgraded; DIS, BMY, MON, AKAM Downgraded
Jan 27, 2009 10:41AM David Moenning's Daily State of the Markets: 1/27
Oct 23, 2008 10:07AM David Moenning's Daily State of the Markets: 10/23